Response to Combivir and abacavir given BID to nucleoside experienced patients is not affected by the presence of the M184V mutation
Originally Published on May 12, 1999
Henry K, Shaeffer M, Ross L, et al.
6th Conference on Retroviruses and Opportunistic Infections. 31 Jan-4 Feb, 1999, Chicago, IL. Abstract 132.
ABSTRACT: Background: TARGET is a study of a compact regimen of Combivir (lamivudine 150 mg/ zidovudine 300 mg) [CBV] plus Ziagen (TM) (abacavir 300 mg) [ABC] in patients that were on mono- or double-combination NRTI's. Objective: To assess the impact of the M184V mutation on HIV-1 RNA response in NRTI experienced patients treated with CBV and ABC. Design: Genotypic sequencing is planned for all baseline plasma samples and has been completed on 62/87 samples. HIV-1 RNA response in patients with viral isolates positive for M184V mutation were compared to those without the mutation.
Results: Median baseline HIV-1 RNA for the entire population (N=87) was 1259 c/mL and 50 c/mL at week 16. 59.7% (37/62) of patients were positive for M184V. Median viral load for patients positive and negative for the mutation was 3531c/mL and 4420 c/mL at baseline, and 137 c/mL and 69 c/mL at week 16 respectively. Change in HIV-1 RNA from baseline was not significantly different between the two groups (P=0.131, two-sample t test). At week 16 there was also no significant difference in the proportion <50 c/mL HIV-1 RNA between the two groups (P = 0.727). Conclusion: Initial HIV-1 RNA response to therapy with CBV and ABC in NRTI experienced patients is not significantly different in patients with or without the M184V mutation at baseline.
